Park Square is pleased to announce the placement of Brandi Simpson as Senior Vice President, Business Development at Switch Therapeutics. Switch Therapeutics is a venture-backed biotechnology company that is developing a new generation of RNAi therapies based on revolutionary technology developed at Caltech, City of Hope, and Harvard Medical School.

Simpson is a broadly experienced business-oriented biotechnology executive with impressive academic credentials and solid career underpinnings in investment banking and strategy consulting. She most recently served as Vice President, Corporate and Business Development at Voyager Therapeutics, a publicly traded gene therapy company focused on developing treatments for central nervous system diseases. In this role, she led major licensing agreements with several large pharma companies, including Novartis and Pfizer. Previously, Simpson held roles of increasing responsibility at Navigen, joining the company as Chief Business Officer and ultimately serving as Chief Executive Officer. 

Simpson received her M.B.A. from Stanford University and her B.S. degree in Finance at the University of Utah.

Brandi’s appointment represents the latest in a series of executive placements that Park Square has undertaken with Switch, having recently recruited several key members of the leadership team and Board.